Back to All Resources

Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases

August 16, 2023

American Chemical Society (ACS) Fall 2023 Meeting

Kymer ACS Presentation Image
View Presentation
Area of Focus
Immunology
Programs
IRAK4 (KT-474)
Indications
Hidradenitis Suppurativa (HS) Atopic Dermatitis (AD)
Development Stage
Pre-clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Hidradenitis Suppurativa (HS) Atopic Dermatitis (AD)
View Resource
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
Hidradenitis Suppurativa (HS) Atopic Dermatitis (AD)
View Resource
May 18, 2023
Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis
European Academy of Dermatology & Venereology (EADV) Symposium 2023
Hidradenitis Suppurativa (HS) Atopic Dermatitis (AD)
View Resource